HERCA
HEADS OF THE EUROPEAN RADIOLOGICAL PROTECTION COMPETENT AUTHORITIES

HERCA Multi-Stakeholder Workshop on Generic Justification

Plenary Session 1:

How can Health Technology Assessment (HTA) contribute to the justification process of new types of practices?

Co-Chairs:

Eva G. Friberg (NRPA) and Ritva Bly (STUK)

HERCA WGMA
Paris, 24-6th of October 2016

Health Technology Assessment (HTA)

- HTA – a systematic evaluation of
  - Available knowledge on safety and clinical effect
  - Cost-effectiveness
  - Ethical, social, organizational and juridical aspects
- HTA – a tool for decision-making
  - Introduction of new methods
  - Phase-out of methods no longer considered clinical effective or safe

Integrate Generic Justification into HTA

Rationale:

- Risk-benefit evaluation in generic justification similar to total risk/benefit assessment already performed in HTA
  - Integrate radiation detriment in total risk-assessment
- Bringing together all assessments/evaluation in one process
  - All aspects taken into account in the final decision-making process
- Bringing together relevant stakeholders
  - Cooperation between RP authorities and HTA bodies

Questions to be discussed

- How can HTA contribute to the justification process of new types of practices?
  - What are the strength of the HTA approach?
  - What are the potential weak points of the HTA approach?
  - How could these weak points be strengthened within the HTA approach
    - by Radiation Protection Authorities on a MS level?
    - by HERCA on an European level?

Outline of Session

- European Health Technology Assessment (HTA): Advantages and Experiences
  - Ulla Saalasti-Koskinen (National Institute for Health and Welfare)
  - Ritva Bly (Finnish Radiation and Nuclear Safety Authority)
- Case Study: National System on HTA in Norway
  - Øyvind Melien (Norwegian Directorate of Health)
  - Eva G. Friberg (Norwegian Radiation Protection Authority)
- Feedback from Medical Associations and Manufacturers
- Round Table Discussion